4,4-diethyl-2,6-dioxo-piperidine-3,5-dicarbonitrile | 80721-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4,4-diethyl-2,6-dioxo-piperidine-3,5-dicarbonitrile
• 英文别名: 4,4-Diaethyl-2,6-dioxo-piperidin-3,5-dicarbonitril；4,4-Diethyl-2,6-dioxopiperidine-3,5-dicarbonitrile
• CAS: 80721-13-7
• 化学式: C₁₁H₁₃N₃O₂
• mdl: MFCD04090149
• 分子量: 219.243
• InChiKey: FBTAXAUKVNXAEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.636
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4-diethyl-2,6-dioxo-piperidine-3,5-dicarbonitrile 在 溴 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以94%的产率得到6,6-diethyl-2,4-dioxo-3-azabicyclo[3.1.0]hexane-1,5-dicarbonitrile
  参考文献：
  名称：

  瓜雷基酰亚胺的化学和电催化级联环化：“一锅”简单有效的方法制备2,4-二氧代-3-氮杂双环[3.1.0]己烷骨架

  摘要：

  在存在溴化钠作为介体的情况下，在未分裂的细胞中，瓜尔基酰亚胺在乙醇中的电解可快速有效地环化，形成80-98％的取代的3-氮杂双环[3.1.0]己烷系统。快速（30分钟）的电催化反应在中性和温和条件下平稳进行。在级联环化反应中使用电催化是医学上有用的3-氮杂双环[3.1.0]己烷骨架的有效方法，避免了分子卤素或卤代底物直接使用的不便，并且从多样性导向的角度出发也是有益的大规模的过程。

  DOI：

  10.1016/j.tet.2013.04.035
• 作为产物：
  描述：

  2-氰基-3-乙基-2-戊酸乙酯 在 sodium 、 氰乙酰胺 作用下， 以 乙醇 为溶剂， 以64%的产率得到4,4-diethyl-2,6-dioxo-piperidine-3,5-dicarbonitrile
  参考文献：
  名称：

  [EN] SULFONANILIDE AND BENZYLSULFONYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
  [FR] DÉRIVÉS DE SULFONANILIDE ET BENZYLSULFONYLE, ET COMPOSITIONS ET PROCÉDÉS ASSOCIÉS

  摘要：

  这项发明提供了新型磺胺苯胺和苯基磺酰衍生物，以及其制备和使用的组合物和方法，可用于治疗与TRPML活性相关的各种疾病和紊乱，如溶酶体贮积症、肌肉营养不良、与年龄相关的常见神经退行性疾病、氧化应激或与活性氧（ROS）相关的疾病以及衰老。

  公开号：

  WO2022076383A1

文献信息

• Heteroarylakanoic acids as intergrin receptor antagonists
  申请人：——

  公开号：US20040092497A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &agr;&ngr;&bgr; 3 and/or the &agr;&ngr;&bgr; 5 integrin without significantly antagonizing the IIb/IIIa integrin. 1

  本发明涉及一类由式（I）表示的化合物或其药学上可接受的盐、包含式（I）化合物的制药组合物以及选择性拮抗&agr;&ngr;&bgr;3和/或&agr;&ngr;&bgr;5整合素而不显著拮抗IIb/IIIa整合素的方法。
• Heteroarylalkanoic acids as integrin receptor antagonists
  申请人：——

  公开号：US20020133023A1

  公开（公告）日：2002-09-19

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the &agr; V &bgr; 3 and/or the &agr; V &bgr; 5 integrin without significantly antagonizing the IIb/IIIa or &agr; V &bgr; 6 integrin.

  本发明涉及一类由式I1表示的化合物或其药学上可接受的盐，包括式I的药物组合物，并且涉及一种选择性拮抗&agr;V&bgr;3和/或&agr;V&bgr;5整合素而不显著拮抗IIb/IIIa或&agr;V&bgr;6整合素的方法。
• Geminate-substituted cyclopentadienes. 1. Synthesis of 5,5-dialkylcyclopentadienes via 4,4-dialkylcyclopent-2-en-1-ones
  作者：Richard W. Holder、John P. Daub、Wesley E. Baker、Raymond H. Gilbert、Norman A. Graf

  DOI：10.1021/jo00347a013

  日期：1982.4
• Birch; Kon, Journal of the Chemical Society, 1923, vol. 123, p. 2447
  作者：Birch、Kon

  DOI：——

  日期：——
• Synthesis, Pharmacological Characterization, and Quantitative Structure−Activity Relationship Analyses of 3,7,9,9-Tetraalkylbispidines:  Derivatives with Specific Bradycardic Activity
  作者：Uwe Schön、Jochen Antel、Reinhard Brückner、Josef Messinger、Rainer Franke、Andreas Gruska

  DOI：10.1021/jm970120q

  日期：1998.1.1

  A series of 3,7,9,9-tetraalkyl-3,7-diazabicyclo[3.3.1]nonane derivatives (bispidines) was synthesized and identified as potential antiischemic agents. Pharmacological experiments in vitro as well as in vivo are described, and the results are listed. For selection of those compounds fitting best to the desired profile of a specific bradycardic antianginal agent-decrease in heart rate without affecting contractility and blood pressure-these results were scored and ranked. Quantitative structure-activity relationship (QSAR) analyses were performed and discussed a posteriori by means of Hansch, nonelementary discriminant and factor analysis to get insight into the molecular features determining the biological profile. Highly significant equations were obtained, indicating hydrophobic and steric effects. Both pharmacological ranking and QSAR considerations showed compound 6 as the optimum within the structural class under investigation. Compound 6 (tedisamil, KC8857) has been selected as the most promising compound and was chosen for further pharmacological and clinical investigations as an antiischemic drug.